Tag: GSK

GSK’s experimental TB vaccine shows promising results in clinical trials

GSK and Aeras reported that GSK’s M72/AS01E candidate vaccine significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults with latent tuberculosis infection.

GSK to close Stiefel Laboratories manufacturing faclility in Ireland

GlaxoSmithKline plans to close its dermatology subsidiary plant in Sligo (Ireland). The plant is to wind down, with final closure tabled for 2021.

GSK plans to close its Bangladesh manufacturing facility

GlaxoSmithKline, one of the world's leading research-based pharmaceutical and healthcare companies, has decided to close its drug manufacturing unit in Bangladesh after over six decades of operation.

GSK and 23andMe entered an exclusive R&D collaboration

GSK and 23andMe unveiled an exclusive four-year collaboration that will focus on research and development of innovative new medicines and potential cures, using human genetics as the basis for discovery.

Mepolizumab for eosinophilic asthma treatment was registered in Russia

GSK announced the registration of Nucala (mepolizumab) in the Russian Federation to be used as add-on maintenance treatment for severe eosinophilic asthma in patients over 18 years old.

TrialScope will support disclosure and transparency of GSK clinical trials

clinical trials
TrialScope, the global leader in clinical trial transparency and compliance solutions, announced that it has been selected by GlaxoSmithKline plc to facilitate clinical trial disclosure and transparency

GSK started a drug development partnership with Cloud Pharmaceuticals

drug discovery
Cloud Pharmaceuticals, an Artificial Intelligence-driven drug design and development company, entered into drug discovery collaboration with GlaxoSmithKline (GSK).

GSK passes its portfolio of rare disease gene therapies to Orchard Therapeutics

gene therapy
GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients.

GSK will supply medicines worth 1.1 billion rubles to Russian Ministry of Health

Since the start of 2018, GlaxoSmithKline Trading CJSC, the Russian division of British GSK, has won five competitive bids to supply the drugs against HIV, hepatitis B, C and tuberculosis.

Novartis sells its stake in consumer healthcare joint venture to GSK

Novartis announced that it has entered into an agreement with GlaxoSmithKline (GSK) to divest its 36.5 percent stake in its consumer healthcare joint venture (JV) to GSK for $13.0 billion.

Syngene International will work with GSK to advance drug discovery

drug discovery
Syngene International, a leading global contract research services company, announced an R&D agreement with GSK, a science-led global healthcare company. The agreement will focus on the discovery of new drug candidates.

GSK will use clinical trial software solutions from Covance Drug Development

LabCorp, a leading global life sciences company, announced that its Covance Drug Development business has entered into a strategic technology agreement with GlaxoSmithKline

EMA recommended GSK’s Shingrix for marketing authorization

european medicines agency
GlaxoSmithKline announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for Shingrix for the prevention of shingles (herpes zoster)

GlaxoSmithKline launches its HIV drug in China

British pharmaceutical giant GlaxoSmithKline has officially launched its blockbuster triple-therapy HIV drug in China, pricing it lower than in neighboring markets

Plasticell and Anthony Nolan to partner in clinical trials of stem cell product

Plasticell today announced it will collaborate with Anthony Nolan, a leading research organisation dedicated to saving the lives of people with blood cancers

Plasticell and GSK sign agreement to produce hematopoietic cells from iPSCs

In the collaboration, Plasticell will use its CombiCult® technology to screen combinations of molecules provided by GSK to identify and optimise iPSC differentiation protocols.